NCT06464692: An ongoing trial by AbbVie
This trial is ongoing. It must report results 3 years, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06464692 |
|---|---|
| Title | A Phase 1b Study to Evaluate Safety and Pharmacokinetics (PK) of Telisotuzumab Adizutecan (ABBV-400) in Chinese Subjects With Unresectable Locally Advanced/Metastatic Colorectal Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 30, 2024 |
| Completion date | Sept. 30, 2028 |
| Required reporting date | Sept. 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |